Lexicon Pharmaceuticals, Inc. Aktie News

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter

Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study

Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter

THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Okay. Welcome back, eve...

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held Sept...

THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology (ESC) 2025 Congress in Madrid, Spain.